Plasma Cell Leukemia Medical Services in China

Plasma Cell Leukemia (PCL) is a rare and aggressive hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the peripheral blood, with ≥20% plasma cells or an absolute plasma cell count ≥2 × 10⁹/L. It exists in two forms: primary PCL (de novo, accounting for ~60% of cases) and secondary PCL (evolving from pre-existing multiple myeloma, typically indicating end-stage disease and poorer prognosis). Pathogenetically, PCL arises from genetic instability in terminally differentiated B-lymphocytes, with frequent high-risk cytogenetic abnormalities including del(17p), t(11;14), t(14;16), gain(1q), and hyperdiploidy. Dysregulation of key pathways—such as NF-κB, MAPK, and PI3K/AKT—drives uncontrolled survival, proliferation, and evasion of apoptosis. Bone marrow microenvironment interactions, particularly via CXCR4/CXCL12 and VLA-4/VCAM-1 axes, further promote tumor cell homing, adhesion-mediated drug resistance, and extramedullary dissemination. Epidemiologically, PCL represents <1% of all plasma cell disorders and ~2–4% of all leukemias; incidence is approximately 0.04–0.12 per 100,000 persons annually. Median age at diagnosis is 60–65 years, with a slight male predominance (M:F ≈ 1.3:1). Risk factors include advanced age, prior monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), exposure to ionizing radiation or certain industrial chemicals (e.g., benzene), and immunosuppression (e.g., post-transplant). Unlike typical multiple myeloma, PCL often presents with rapid-onset systemic symptoms: profound fatigue, recurrent infections (due to hypogammaglobulinemia), bleeding diathesis (thrombocytopenia), renal insufficiency (light-chain cast nephropathy), bone pain (less prominent than in myeloma), and hepatosplenomegaly or lymphadenopathy reflecting extramedullary involvement. Quality of life is severely compromised—patients experience debilitating anemia-related dyspnea and cognitive fog, neuropathic pain from amyloidosis or treatment toxicity, emotional distress linked to poor prognostication (median overall survival: 11–18 months in primary PCL; <6 months in secondary PCL), and significant functional decline requiring caregiver support. Treatment-related toxicities—including cytopenias, neurotoxicity from proteasome inhibitors, and infection risk from immunomodulatory agents—further erode daily functioning, social engagement, and occupational capacity. Early palliative integration, psychosocial support, and symptom-directed care are essential components of comprehensive management.

Plasma Cell Leukemia (PCL) is a rare and aggressive plasma cell dyscrasia characterized by the presence of ≥20% clonal plasma cells in the peripheral blood and/or an absolute plasma cell count ≥2 × 10⁹/L. It exists in two forms: primary PCL (de novo, accounting for ~60% of cases) and secondary PCL (evolving from pre-existing multiple myeloma, associated with poorer prognosis). As a hematologic malignancy managed within the Department of Hematology, PCL demands rapid diagnosis—via peripheral blood smear, bone marrow aspiration/biopsy, serum/urine protein electrophoresis, immunofixation, free light chain assay, cytogenetics (FISH), and next-generation sequencing—and urgent, risk-adapted therapeutic intervention.

Conservative treatment plays a supportive yet indispensable role in PCL management. Given the high tumor burden, patients frequently present with hypercalcemia, renal insufficiency, anemia, and thrombocytopenia (CRAB features), alongside hyperviscosity syndrome and coagulopathy. Conservative measures include aggressive intravenous hydration (2–3 L/day) with forced diuresis (furosemide if euvolemic), bisphosphonates (zoledronic acid 4 mg IV monthly) to mitigate skeletal events, erythropoiesis-stimulating agents (e.g., darbepoetin alfa) for symptomatic anemia, platelet transfusions for counts <10 × 10⁹/L or active bleeding, and broad-spectrum antimicrobial prophylaxis (e.g., levofloxacin, acyclovir, and pneumocystis jirovecii prophylaxis with trimethoprim-sulfamethoxazole) due to profound immunosuppression. Plasmapheresis may be employed emergently for symptomatic hyperviscosity (serum viscosity >4.0 cP) or acute kidney injury with cast nephropathy, though it does not alter disease biology and must be combined with definitive anti-myeloma therapy.

Pharmacotherapy constitutes the cornerstone of PCL treatment. Induction regimens are intensive and typically triplet-based, incorporating a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide or pomalidomide), and dexamethasone (VRd or KRd). For fit patients, quadruplet regimens such as daratumumab–lenalidomide–bortezomib–dexamethasone (DRdV) or isatuximab–carfilzomib–lenalidomide–dexamethasone (Isa-KRd) demonstrate superior depth of response and progression-free survival. High-dose melphalan (200 mg/m²) followed by autologous stem cell transplantation (ASCT) remains standard consolidation for eligible patients (age <70 years, adequate organ function), achieving complete response (CR) rates of 50–70%. Maintenance therapy post-ASCT—typically lenalidomide (10 mg daily, 21 days on/7 off) or bortezomib-based regimens—is recommended indefinitely or until progression. For transplant-ineligible or relapsed/refractory PCL, novel agents including BCMA-directed therapies (belantamab mafodotin, teclistamab, cilta-cel CAR-T) show unprecedented efficacy; cilta-cel achieved an overall response rate of 97% and median progression-free survival of 34.2 months in the CARTITUDE-1 trial. Bruton tyrosine kinase inhibitors (e.g., ibrutinib) and venetoclax (BCL-2 inhibitor) are under investigation in biomarker-selected subsets (e.g., t(11;14)).

Surgical treatment has no direct role in PCL pathophysiology. However, surgical interventions may be required for complications: orthopedic stabilization for pathological vertebral or long-bone fractures, nephrostomy tube placement for obstructive uropathy, or central venous catheter insertion for reliable vascular access during intensive chemotherapy and ASCT. Rarely, splenectomy may be considered in refractory autoimmune cytopenias, though evidence is anecdotal and risks outweigh benefits in most PCL cases.

Treatment advantages in China are multifaceted and increasingly internationally recognized. First, China’s national hematologic malignancy networks—such as the Chinese Myeloma Working Group (CMWG)—have standardized diagnostic criteria and treatment protocols aligned with IMWG and NCCN guidelines, ensuring consistent, evidence-based care across tier-1 hospitals (e.g., Peking University People’s Hospital, Ruijin Hospital). Second, China leads globally in CAR-T cell therapy accessibility: over 30 BCMA-targeted CAR-T products are in clinical development, and commercially approved therapies (e.g., equecabtagene autoleucel) are reimbursed under provincial medical insurance schemes, reducing out-of-pocket costs by >60%. Third, China’s robust generic pharmaceutical industry enables rapid, cost-effective production of bortezomib, lenalidomide, and daratumumab biosimilars—reducing induction regimen costs by 40–65% versus Western markets without compromising pharmacokinetic equivalence. Fourth, integrated traditional Chinese medicine (TCM) adjuncts—such as Jianpi Bushen decoctions—are rigorously studied in randomized trials and shown to reduce chemotherapy-induced neutropenia and fatigue, improving treatment adherence and quality of life. Finally, China’s centralized biobanking and AI-driven genomic platforms (e.g., BGI’s hematologic oncology database) facilitate real-time molecular monitoring and early detection of resistance mutations (e.g., PSMB5, CRBN), enabling dynamic therapy adjustment.

Recovery advice emphasizes longitudinal, multidisciplinary engagement. Patients should undergo scheduled hematologic assessments every 4–8 weeks during active therapy and every 3 months during maintenance, including CBC, serum creatinine, calcium, β₂-microglobulin, serum free light chains, and minimal residual disease (MRD) testing via next-generation flow cytometry or sequencing. Bone health must be prioritized: daily calcium (1200 mg) and vitamin D₃ (800–1000 IU), weight-bearing exercise, and dual-energy X-ray absorptiometry (DEXA) scans annually. Infection prevention includes annual influenza and pneumococcal vaccination (PCV20), strict hand hygiene, avoidance of raw seafood/unpasteurized dairy, and prompt reporting of fever (>38.0°C). Psychosocial support is critical—referral to certified oncology counselors and peer-led survivorship programs improves coping and reduces depression prevalence by 35% in longitudinal studies. Nutrition counseling should emphasize high-protein, low-sodium, low-purine diets to support hematopoietic recovery and prevent uric acid nephropathy. Finally, fertility preservation (sperm/egg cryopreservation) must be discussed prior to alkylator-based induction or ASCT, particularly in patients <40 years. With contemporary regimens, median overall survival has improved from <12 months (pre-2000) to 36–48 months in primary PCL and 24–30 months in secondary PCL—underscoring the imperative of timely, protocol-driven, and patient-centered care.